Sunday 18 October 2026
Export ENGN’s income statement to Excel — free account
enGene Therapeutics Inc
ENGN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 18.2%, free cash flow grew 28.1% and total debt rose 42.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.67
0.04
−2.34%
Follow ENGN
| Oct '25 | Oct '24 | Oct '23 | Dec '22 | Oct '22 | Dec '21 | Oct '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
6.30 | 16.87 | 16.25 | 0.57 | 4.42 | 4.79 | 46.20 | — |
Net Debt/EBITDA |
1.42 | 3.47 | 2.80 | 0.17 | (0.54) | 0.00 | — | — |
Debt/Assets |
6.92% | 7.22% | 10.60% | 0.00% | 129.01% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.09 | 0.08 | 0.13 | 0.00 | (0.40) | 0.00 | — | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.85 | 0.88 | 0.24 | (24.60) | 0.61 | 0.00 | 0.00 | — |
Capex/Depreciation |
0.58 | (10.16) | (1.82) | — | (0.64) | 0.00 | 0.00 | — |
Interest Coverage |
(41.14) | (22.26) | (5.26) | (0.98) | (13.65) | — | — | — |
| (53.28%) | (31.96%) | (306.36%) | (0.08%) | 73.58% | 0.00% | — | — | |
| (44.05%) | (27.70%) | (95.65%) | 0.04% | (37.36%) | (0.34%) | 0.00% | — | |
ROIC |
0.00% | (68.69%) | (15,511.90%) | 0.00% | 0.00% | 0.00% | — | — |
Return on Tangible Assets |
(68.24%) | (23.58%) | (129.67%) | (8.04%) | (162.45%) | (18.17%) | 0.00% | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | — | — | — |
Free Cash Flow per Share |
(1.97) | (1.30) | (36.16) | (0.24) | (27.08) | 0.00 | 0.00 | — |
Cash per Share |
3.79 | 6.31 | 117.74 | 0.10 | 31.30 | 0.07 | — | — |
Shareholders Equity per Share |
3.28 | 7.22 | 104.60 | (1.30) | (116.93) | (0.14) | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
3.28 | 7.22 | 104.60 | (1.30) | (116.93) | (0.14) | — | — |
Free Cash Flow |
(100.72) | (49.21) | (25.06) | (0.76) | (17.74) | 0.00 | 0.00 | — |
Working Capital |
169.41 | 232.70 | 80.18 | (0.38) | 17.48 | 1.24 | 0.49 | — |
Capital Expenditures |
(1.48) | (0.92) | (0.32) | — | (0.15) | 0.00 | 0.00 | — |
Net Current Asset Value |
147.63 | 208.80 | 70.97 | (135.64) | (77.94) | (132.16) | 0.49 | — |
| Other line items | ||||||||
Quick Ratio |
6.09 | 16.28 | 15.97 | 0.35 | 4.28 | 3.27 | 0.00 | — |
Depreciation/Fixed assets |
(1.03) | 0.08 | 0.30 | — | 0.62 | 0.00 | 0.00 | — |
Cash ROIC |
(26.73%) | (9.22%) | (15.35%) | 19.90% | 70.25% | 0.00% | 0.00% | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(1.94) | (1.28) | (35.70) | (0.24) | (26.85) | 0.00 | 0.00 | — |
Capex per Share |
(0.03) | (0.02) | (0.46) | 0.00 | (0.23) | 0.00 | 0.00 | — |
Average Receivables |
0.63 | 1.34 | 1.84 | — | — | — | — | — |
Average Payables |
4.05 | 1.28 | 0.94 | — | — | — | — | — |
Average Assets |
266.32 | 199.07 | 109.50 | 77.98 | 77.68 | 65.97 | 0.25 | — |
Average Common Equity |
220.16 | 172.55 | 34.19 | (40.36) | (39.45) | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026